To clarify the regulatory terminology: "Tier 2" (Class II) is simply the FDA’s device classification based on medical risk. The actual accelerated framework for diagnostics is the FDA's Breakthrough Devices Program.Quote:LifetracDX isn't FDA approved, so no Medicare coverage... yet. There is something called a Tier 2 FDA authorization, which I think is like an accelerated approval for diagnostic tests. I suspect CreatvBio's association with Cytodyn will soon lead to something like Tier 2 approval for LifeTracDx, with further Phase 3 testing before it gets full approval. Meanwhile, Signatera can validate a patients ctDNA right now.
While both biomarker platforms serve a viable purpose, the Natera deal is significantly more valuable for a few definitive reasons:
1) Gold-Standard Validation: Unlike investigational assays, Signatera is already FDA-approved and recognized as the gold standard for ctDNA tracking.
2) Regulatory Fast Track: It can—and in my opinion, will—serve as a validated surrogate endpoint to support an Accelerated Approval (AA) or a Breakthrough Therapy Designation (BTD).
3) The Big Pharma Telemetry Loop: Natera’s existing partnerships with Merck (and other Big Pharma leaders) mean they will likely have early, live data points of leronlimab's molecular response data. This could easily trigger a strategic partnership before official results are released to the public.
Personally, I welcome an early upfront partnership to fund operations, but I want any actual buyout offers to execute after the locked results and the formal FDA Type B meeting. Waiting for those milestones is what will truly unlock maximum share price value for investors.
Disclosure: This reflects my bullish investment perspective and should not be interpreted as financial advice.
19
